FOLD Forecast



Bearish<—>Bullish



80% Confidence




Bullish Case: Amicus Therapeutics' recent exclusive license for DMX-200, combined with projected revenue growth and high implied volatility, provides a promising upside for FOLD. Strong pipeline development can further enhance stock potential.




Bearish Case: FOLD faces significant downside risks, with historic declines and high implied volatility indicating market skepticism. Financial misses and increasing competitive pressure can exacerbate investor concerns.




Potential Outcomes:
  • 40%: Regulatory success boosts revenue and stock price.
  • 30%: Continued financial struggles press stock lower.
  • 20%: Moderate fluctuations amid market volatility.
  • 10%: Strategic setbacks drive price decline.




Trading Oracle: Sign Up to access trading oracle trade ideas.



May 15, 2025


Amicus Therapeutics Forecast

FOLD        Amicus Therapeutics
















Become a more profitable investor with AI optimized trading strategies






×

Chat with FOLD


 Ask any question about FOLD!